#moderna
moderna
3,590 views
10 Discussing
Hot
Latest
#modernarisesover12% 🚀 $MRNAon
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
Breaking Out! 🔥
$MRNA surged 12%+ after strong bullish catalysts: ✅ FDA panel backs its mRNA flu vaccine ✅ Analysts raise target to $77 ✅ Pipeline momentum remains strong
📈 Smart move: Wait for a healthy pullback instead of chasing the pump.
Are you bullish on $MRNAon ? 👇
#MRNA #Moderna #Biotech
AngelOfCrypto_-:
👍👍👍👍👍
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS-0.46%
🚀 MODERNA SURGES OVER 12%! Hits New 52-Week High 🧬
Moderna ($MRNAon ) stock just experienced a massive rally, jumping over 12% to reach a 52-week high of $67.78.
💥 What Triggered the Rally?
Pipeline Progress & Price Target Hikes: Following Moderna's recent Science Day presentation highlighting research on cancer antigen therapies, Piper Sandler raised its price target on the stock from $69 to $77 and maintained an Overweight rating.
FDA Panel Backing: The FDA's vaccine advisory panel recently voted unanimously to recommend approval for Moderna's proposed mRNA flu vaccine (mRNA-1010) for adults aged 50 to 64, with support for accelerated approval for those 65 and older.
International Sales Boost: International demand for Moderna's COVID-19 vaccine has risen, which offset domestic sales declines and boosted first-quarter revenue beyond Wall Street expectations.
Options Frenzy: Options trading activity surged significantly, with 121,257 contracts traded. The most active contract was the June 18, 2026, $65 call.
📊 The Macro Picture:
The biotech giant has engineered a stunning turnaround in 2026. After hitting a 52-week low of $22.28, the stock has skyrocketed, logging a 145.18% gain over the past year and a 103% return year-to-date.
#ModernaRisesOver12% #moderna #stockmarket #Biotech #TradingNews
$VELVET
$BEAT
Moderna ($MRNAon ) stock just experienced a massive rally, jumping over 12% to reach a 52-week high of $67.78.
💥 What Triggered the Rally?
Pipeline Progress & Price Target Hikes: Following Moderna's recent Science Day presentation highlighting research on cancer antigen therapies, Piper Sandler raised its price target on the stock from $69 to $77 and maintained an Overweight rating.
FDA Panel Backing: The FDA's vaccine advisory panel recently voted unanimously to recommend approval for Moderna's proposed mRNA flu vaccine (mRNA-1010) for adults aged 50 to 64, with support for accelerated approval for those 65 and older.
International Sales Boost: International demand for Moderna's COVID-19 vaccine has risen, which offset domestic sales declines and boosted first-quarter revenue beyond Wall Street expectations.
Options Frenzy: Options trading activity surged significantly, with 121,257 contracts traded. The most active contract was the June 18, 2026, $65 call.
📊 The Macro Picture:
The biotech giant has engineered a stunning turnaround in 2026. After hitting a 52-week low of $22.28, the stock has skyrocketed, logging a 145.18% gain over the past year and a 103% return year-to-date.
#ModernaRisesOver12% #moderna #stockmarket #Biotech #TradingNews
$VELVET
$BEAT
Moderna Stock ($MRNAon ) Rises Over 12%! Here is Why 👇
Moderna stock jumped a massive 12.59% on Friday, closing at $67.27! Here are the 2 main reasons behind this huge surge:
1️⃣ FDA Panel Approval: The US FDA advisory committee unanimously voted 9-0, recommending Moderna's new mRNA-based seasonal flu vaccine (mFlusiva). They agreed that its benefits far outweigh the risks.
2️⃣ High Efficacy: Phase 3 trials showed this new vaccine is 26.6% to 27% more effective than traditional egg-based flu shots.
This is a big win for mRNA technology! 🚀
Urdu summary:
Moderna’s stock rose more than 12% on Friday to close higher. The reason for this big surge is their new flu vaccine (mFlusiva), which the US FDA panel has unanimously recommended for approval. This new vaccine has proven to be 27% more effective than older vaccines.
#ModernaRisesOver12% #Moderna
#stockmarket #CryptoNewss #BinanceSquare
Moderna stock jumped a massive 12.59% on Friday, closing at $67.27! Here are the 2 main reasons behind this huge surge:
1️⃣ FDA Panel Approval: The US FDA advisory committee unanimously voted 9-0, recommending Moderna's new mRNA-based seasonal flu vaccine (mFlusiva). They agreed that its benefits far outweigh the risks.
2️⃣ High Efficacy: Phase 3 trials showed this new vaccine is 26.6% to 27% more effective than traditional egg-based flu shots.
This is a big win for mRNA technology! 🚀
Urdu summary:
Moderna’s stock rose more than 12% on Friday to close higher. The reason for this big surge is their new flu vaccine (mFlusiva), which the US FDA panel has unanimously recommended for approval. This new vaccine has proven to be 27% more effective than older vaccines.
#ModernaRisesOver12% #Moderna
#stockmarket #CryptoNewss #BinanceSquare
BREAKING: Moderna says it’s working on a Hantavirus vaccine.
The market is paying attention for one reason:
Every new outbreak instantly becomes a biotech and government funding race.
COVID changed the playbook forever.
Now vaccine makers move before panic fully arrives because speed is power, money, and geopolitical leverage.
If Hantavirus headlines keep escalating, Moderna could once again become a central player in global health response infrastructure.
And investors know what happens when fear, urgency, and biotech innovation collide:
volatility explodes overnight.
The world learned the cost of being unprepared.
This time, the response starts early.
#Moderna #Hantavirus #Biotech #BreakingNews #Stocks
The market is paying attention for one reason:
Every new outbreak instantly becomes a biotech and government funding race.
COVID changed the playbook forever.
Now vaccine makers move before panic fully arrives because speed is power, money, and geopolitical leverage.
If Hantavirus headlines keep escalating, Moderna could once again become a central player in global health response infrastructure.
And investors know what happens when fear, urgency, and biotech innovation collide:
volatility explodes overnight.
The world learned the cost of being unprepared.
This time, the response starts early.
#Moderna #Hantavirus #Biotech #BreakingNews #Stocks
Log in to explore more content